Alnylam Pharmaceuticals Inc.

NASDAQ-GS: ALNY

.USD

+7.73 (2.42%)↑ today

Price at Apr 8, 4:00:01 PM EDT • Market Closed

Is it expensive?

Trailing P/E Ratio

Explainer

Trailing P/E shows what you are paying for each dollar of last year's earnings. It answers: "How expensive is this stock relative to its past year's profits?"

P/E Ratio: The expensive truth about cheap stocks

136.85

Forward P/E Ratio

Explainer

Forward P/E shows what you are paying for each dollar of next year's projected earnings. It answers: "How expensive is this stock relative to its expected future profits?"

P/E Ratio: The expensive truth about cheap stocks

22.45

PEG Ratio

Explainer

PEG Ratio measures if a stock is expensive relative to its growth rate. It answers: "Am I paying a fair price for growth?"

PEG Ratio: The growth hunter's best friend

22.45

Enterprise Value to EBITDA

76.00

Price-to-Sales (TTM)

Explainer

Price-to-Sales (TTM) shows what you pay for each dollar of the company's revenue. It answers: "How expensive is this stock relative to sales?"

11.39

Price-to-Book (MRQ)

53.48

Book Value per Share (MRQ)

5.96

Market Cap

Explainer

Market Cap calculates a company's market value. It answers: "How big is this company and what size risk am I taking?"

Market Cap: Sometimes size does matter

42.38B

Enterprise Value

42.35B

Is it profitable?

Net Profit Margin (TTM)

Explainer

Net Profit Margin (TTM) shows what percentage of revenue remains after all costs. It answers: "How much does the company keep as a final profit?"

Profit Margin: The key to measuring true business profitability

8.45%

Gross Profit Margin

Explainer

Gross Profit Margin shows what percentage of revenue remains after direct costs. It answers: "How much does the company keep before operating costs?"

Profit Margin: The key to measuring true business profitability

75.60%

Diluted EPS (TTM)

Explainer

Diluted EPS (TTM) shows the profit per share over the last 12 months. It answers: "How profitable is each share I buy?"

Earnings per Share (EPS): The Key Metric That Beats Headline Profits

2.33

Return on Equity (TTM)

73.28%

Revenue (TTM)

3.71B

Is it growing?

Revenue Growth (MRQ)

84.90%

Earnings Growth (YOY)

84.95%

Is it risky?

Beta

0.38

Debt to Equity (MRQ)

376.19

Current Ratio (MRQ)

2.76

Total Debt (MRQ)

2.97B

Who owns it?

Institutional Ownership

101.74%

Insider Ownership

0.47%

Short Interest

4.33%

Shares Outstanding

132.38M

Shares Float

132.08M

Does it pay?

Forward Dividend Yield

0.00%

Payout Ratio

0.00%

Ex. Dividend Date

Dividend Date

How much cash?

Total Cash (MRQ)

2.91B

Operating Cash Flow (TTM)

524.08M

Levered Free Cash Flow (TTM)

128.79M

Total Cash per Share (MRQ)

21.93

Indicators

Founder-operated companies generally perform better.

Founders

Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, Phillip Zamore, John Kennedy Clarke, Christoph Westphal

CEO

Yvonne L. Greenstreet

Biotechnology

Operating Cash Flow

524.08M

÷0

Net Income

313.75M

Real Earnings

1.67

Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.

Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.

Indicators

Founder-operated companies generally perform better.

Founders

Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, Phillip Zamore, John Kennedy Clarke, Christoph Westphal

CEO

Yvonne L. Greenstreet

Biotechnology

Operating Cash Flow

524.08M

÷0

Net Income

313.75M

Real Earnings

1.67

Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.

Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.

Is it expensive?

Trailing P/E Ratio

Explainer

Trailing P/E shows what you are paying for each dollar of last year's earnings. It answers: "How expensive is this stock relative to its past year's profits?"

P/E Ratio: The expensive truth about cheap stocks

136.85

Forward P/E Ratio

Explainer

Forward P/E shows what you are paying for each dollar of next year's projected earnings. It answers: "How expensive is this stock relative to its expected future profits?"

P/E Ratio: The expensive truth about cheap stocks

22.45

PEG Ratio

Explainer

PEG Ratio measures if a stock is expensive relative to its growth rate. It answers: "Am I paying a fair price for growth?"

PEG Ratio: The growth hunter's best friend

22.45

Enterprise Value to EBITDA

76.00

Price-to-Sales (TTM)

Explainer

Price-to-Sales (TTM) shows what you pay for each dollar of the company's revenue. It answers: "How expensive is this stock relative to sales?"

11.39

Price-to-Book (MRQ)

53.48

Book Value per Share (MRQ)

5.96

Market Cap

Explainer

Market Cap calculates a company's market value. It answers: "How big is this company and what size risk am I taking?"

Market Cap: Sometimes size does matter

42.38B

Enterprise Value

42.35B

Is it profitable?

Net Profit Margin (TTM)

Explainer

Net Profit Margin (TTM) shows what percentage of revenue remains after all costs. It answers: "How much does the company keep as a final profit?"

Profit Margin: The key to measuring true business profitability

8.45%

Gross Profit Margin

Explainer

Gross Profit Margin shows what percentage of revenue remains after direct costs. It answers: "How much does the company keep before operating costs?"

Profit Margin: The key to measuring true business profitability

75.60%

Diluted EPS (TTM)

Explainer

Diluted EPS (TTM) shows the profit per share over the last 12 months. It answers: "How profitable is each share I buy?"

Earnings per Share (EPS): The Key Metric That Beats Headline Profits

2.33

Return on Equity (TTM)

73.28%

Revenue (TTM)

3.71B

Is it growing?

Revenue Growth (MRQ)

84.90%

Earnings Growth (YOY)

84.95%

Is it risky?

Beta

0.38

Debt to Equity (MRQ)

376.19

Current Ratio (MRQ)

2.76

Total Debt (MRQ)

2.97B

Who owns it?

Institutional Ownership

101.74%

Insider Ownership

0.47%

Short Interest

4.33%

Shares Outstanding

132.38M

Shares Float

132.08M

Does it pay?

Forward Dividend Yield

0.00%

Payout Ratio

0.00%

Ex. Dividend Date

Dividend Date

How much cash?

Total Cash (MRQ)

2.91B

Operating Cash Flow (TTM)

524.08M

Levered Free Cash Flow (TTM)

128.79M

Total Cash per Share (MRQ)

21.93

Alnylam Pharmaceuticals Inc.

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Indicators

Indicators

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Alnylam Pharmaceuticals Inc.

Stock Details

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Indicators

Indicators

Stock Details

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers